denverinjury.org legal-medical case intake overview
Dates, records and common questions
From General Health Information to Medication Awareness
Public health communication has long focused on providing clear, accessible information about wellness, disease prevention, and the safe use of medications. This foundational approach—rooted in general health literacy—has served as a vital bridge between clinical knowledge and everyday decision-making. Within this broad educational framework, discussions of prescription drug benefits and potential side effects have traditionally been framed in terms of patient awareness and informed consent. As this heritage of health information evolves, a natural progression emerges when we consider the specific pathways through which individuals encounter pharmaceutical therapies. In particular, the context of occupational exposure introduces a distinct layer of consideration. For workers in manufacturing, healthcare, or logistics settings, the administration or handling of certain medications may occur under different protocols than in a standard clinical visit. This shift from a general public health perspective to a more targeted occupational lens allows us to examine how workplace policies, repeated exposure scenarios, and long-term medication use intersect with individual health outcomes. By pivoting from broad educational messaging to the specific realities of workplace-related pharmaceutical exposure, we can better appreciate the nuanced factors that influence patient risk profiles. This transition sets the stage for a focused discussion on how such exposure patterns relate to the development of movement-related conditions, without yet delving into causal mechanisms.
Reglan (Metoclopramide) and Its Mechanism of Action
Metoclopramide, marketed under the brand name Reglan, is a dopamine D2-receptor blocking agent commonly used to treat nausea, vomiting, and gastroparesis (https://pubmed.ncbi.nlm.nih.gov/34712535/). Due to this mechanism of action, metoclopramide can lead to extrapyramidal side effects, including tardive dyskinesia (TD) (https://pubmed.ncbi.nlm.nih.gov/34712535/). Tardive dyskinesia is a hyperkinetic movement disorder caused by the use of dopamine receptor-blocking agents (DRBAs), a category that includes antipsychotics and agents such as metoclopramide used for gastrointestinal dysmotility (https://pubmed.ncbi.nlm.nih.gov/34703232/). The condition is characterized by involuntary movements that include the face, limbs, and trunk, and is associated with increased comorbidities, social stigmatization, and impaired physical and mental health (https://pubmed.ncbi.nlm.nih.gov/34703232/).
FDA Boxed Warning and Clinical Evidence for Reglan-Associated Tardive Dyskinesia
The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Reglan regarding the risk of tardive dyskinesia. The warning states that metoclopramide, including Reglan, can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients treated with metoclopramide, the risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The prescribing information instructs clinicians to use Reglan for the shortest duration of treatment and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The clinical presentation of TD includes potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Importantly, metoclopramide may suppress or partially suppress the signs of TD, and may delay the diagnosis of TD because it may mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect complicates clinical detection and underscores the need for routine monitoring in patients requiring longer-term therapy.
Risk Factors and Duration of Use in Reglan-Associated Tardive Dyskinesia
The relationship between Reglan exposure and TD onset is not strictly limited to chronic use. A case report describes a nulliparous gynecology patient who developed dyskinetic movements after intraoperative administration of a single dose of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/). During further workup after stabilization, she was found to have several risk factors for TD (https://pubmed.ncbi.nlm.nih.gov/34712535/). This case illustrates that while TD occurrence is somewhat rare, it can emerge after a single dose, particularly in individuals with predisposing risk factors (https://pubmed.ncbi.nlm.nih.gov/34712535/). The report aims to discuss the condition, associated risk factors, and differentiation from other diagnoses (https://pubmed.ncbi.nlm.nih.gov/34712535/). Older age is a well-established risk factor for TD. In older persons taking antipsychotics, TD can affect people of all ages, but older age is associated with increased risk of TD and with the emergence of TD occurring after shorter treatment durations and lower dosages of DRBAs (https://pubmed.ncbi.nlm.nih.gov/34703232/). This age-related vulnerability is relevant to Reglan prescribing, as the drug is often used in older populations for gastrointestinal symptoms. Once present, TD tends to persist despite dose adjustment or discontinuation of the offending agent (https://pubmed.ncbi.nlm.nih.gov/34703232/). This persistence highlights the potentially irreversible nature of the condition and the importance of prevention through careful prescribing.
Causation and Clinical Implications for Reglan and Tardive Dyskinesia
From a causation-focused clinical interpretation, the evidence supports a direct pharmacological link between Reglan and TD. The drug’s dopamine D2-receptor blocking action is the mechanistic pathway underlying the development of extrapyramidal symptoms, including TD (https://pubmed.ncbi.nlm.nih.gov/34712535/). The FDA’s boxed warning and warnings and precautions sections explicitly state that metoclopramide, including Reglan, can cause TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk is dose- and duration-dependent, but case reports demonstrate that even single-dose exposure can trigger TD in susceptible individuals (https://pubmed.ncbi.nlm.nih.gov/34712535/). For affected patients, the timeline between exposure and documented health outcomes can vary widely, from acute onset after a single dose to delayed emergence after months of therapy. The potentially irreversible nature of TD, combined with its ability to be masked by the drug itself, creates a challenging clinical scenario that requires vigilant monitoring and early discontinuation at the first sign of symptoms.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.
ICD-10 reference — G24.0
| Code | Description | Source |
|---|---|---|
| G24.0 | Drug-induced tardive dyskinesia | ICD-10-CM |
| G24.01 | Drug-induced subacute dyskinesia | ICD-10-CM |
| G24.02 | Drug-induced tardive dyskinesia | ICD-10-CM |
Quick Comparison
| Aspect | Reglan (Metoclopramide) | Evidence Source |
|---|---|---|
| Mechanism | Dopamine D2-receptor blocker | https://pubmed.ncbi.nlm.nih.gov/34712535/ |
| Risk of TD | Can cause TD, potentially irreversible | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397 |
| Duration of use | Risk increases with duration and cumulative dose | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397 |
| Single-dose risk | Case report of TD after single dose | https://pubmed.ncbi.nlm.nih.gov/34712535/ |
| Age factor | Older age increases risk and shortens time to onset | https://pubmed.ncbi.nlm.nih.gov/34703232/ |
| Monitoring | Routine monitoring advised for long-term use | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397 |
When to Seek Emergency Care
- Long-term use beyond 12 weeks — For symptomatic GERD, maximum duration is 12 weeks; for diabetic gastroparesis, avoid longer than 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
- Masking of TD symptoms — Metoclopramide may suppress or partially suppress signs of TD, delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
- Contraindication in history of TD — Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
- Concomitant use of other DRBAs — Avoid concomitant use of other drugs known to cause TD, EPS, or NMS (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Day-by-Day / Step Guide
- Day 1 — Patient receives single intraoperative dose of metoclopramide — Monitor for any abnormal movements
- Days 1-7 — Development of dyskinetic movements in susceptible individual — Immediate medical evaluation
- Weeks 1-12 — Risk of TD increases with continued use — Periodic reassessment of need for treatment
- After 12 weeks — Long-term use beyond 12 weeks should be avoided — Discontinue if symptoms appear
Common questions
What is the FDA boxed warning for Reglan?
The FDA has issued a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Can a single dose of Reglan cause tardive dyskinesia?
Yes, a case report describes a patient who developed dyskinetic movements after a single intraoperative dose of metoclopramide, though the patient had several risk factors for TD (https://pubmed.ncbi.nlm.nih.gov/34712535/).
What are the risk factors for developing tardive dyskinesia from Reglan?
Risk factors include longer duration of treatment, higher cumulative dosage, and older age. Older age is associated with increased risk and emergence after shorter treatment durations and lower dosages (https://pubmed.ncbi.nlm.nih.gov/34703232/).
Does submitting information create an medical context-client relationship?
No. Submission requests an initial records screening only and does not create an medical context-client relationship.
Case intake form
Selected reference articles
- Texas Enfamil Necrotizing Enterocolitis injury lawyer
- Pennsylvania Reglan Tardive Dyskinesia injury lawyer
- Does Reglan cause Tardive Dyskinesia
- Does Tysabri cause Progressive Multifocal Leukoencephalopathy
- Statute of limitations for Zoloft in Arizona
Risk & Litigation Archive Index
Browse 5 reference pages across 4 medical-legal topics. Select a topic to view condition-specific case and causation pages.
This list is refreshed periodically whenever new reference entries are added.
Continuity statement: Continuity statement: This archive maintains previously edited reference entries for those researching scientific and historical topics. Presentation may be refreshed over time while the underlying facts are kept intact.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.